Detailed interpretation of Brivaracetam/Brivaracetam drug instructions

1. Drug Overview and Mechanism of Action

Brivaracetam/Brivaracetam is a new anti-epileptic drug with a chemical structure of pyrrolidine amide derivatives. Its main target is synaptic vesicle protein 2A (SV2A) in the central nervous system. Brivaracetam binds with SV2A with high affinity to regulate the balance of neurotransmitter release in neurons, thereby reducing the frequency and intensity of epileptic seizures. Compared with the previous generation drug levetiracetam, brivaracetam has stronger affinity for SV2A, faster onset of action, and better ability to penetrate the blood-brain barrier.

2. Scope of indications

Brivaracetam is approved for the treatment of partial seizures (partial-onset epilepsy), with or without secondary generalized seizures, in patients 1 month of age and older. The drug can be used as a monotherapy or in combination with other anti-epileptic drugs, especially in patients who have a poor response to or intolerance to traditional drugs.

3. Drug dosage forms and interchangeability

Brivaracetam is available in three dosage forms: oral tablets, oral solution, and intravenous solution. These three dosage forms can be used interchangeably in clinical practice, making treatment more flexible and especially suitable for continued maintenance treatment in special circumstances such as hospitalization or inability to take oral medication.

4. Adult usage and dosage

The starting dose is 50 mg twice daily. Based on the patient's treatment response and tolerance, the maintenance dose can be adjusted to 25-100 mg twice daily, with a maximum dose of 200 mg daily. When the oral route is not feasible, intravenous injection can be used. The injection time can be controlled within 2 to 15 minutes, and the administration frequency is the same as oral administration. The intravenous dosage form is recommended to be used for no more than 4 days.

5. Usage and dosage for children

ForChildren 1 month to 16 years of age, dosage is calculated exactly based on body weight:

(1) Body weight <11 kg: initial 0.75-1.5 mg/kg, maintenance 0.75-3 mg/kg, twice a day;

(2) Body weight11-20 kg: initial 0.5-1.25mg/kg, maintenance 0.5-2.5mg/kg, twice a day;

(3) Body weight20-50 kg: initial 0.5-1mg/kg, maintenance 0.5-2mg/kg, twice a day;

(5) Body weightAdolescents ≥50 kg or ≥16 years old: The dosage is the same as for adults, that is, 25-100mg twice daily;

Children's weight changes rapidly, and the dosage should be regularly evaluated and adjusted to ensure efficacy and safety.

6. Drug onset and treatment duration

Brivaracetam has a rapid onset of action, and some patients can feel the anti-epileptic effect within a few hours, so it is often used in situations where seizures need to be controlled quickly. Its half-life is approximately 9 hours, supporting a twice-daily dosing regimen. It is generally recommended that patients continue to use it for several weeks to observe its long-term effect on seizure frequency.

7. Common adverse reactions

Brivaracetam was generally well tolerated. The most commonly reported adverse reactions include headache, drowsiness, dizziness, fatigue, nausea and behavioral changes. Some patients may experience central nervous system symptoms such as anxiety, depression or agitation, so emotional and behavioral changes need to be closely observed during use, especially in children and adolescents.

8. Drug interactions

Brivaracetam is metabolized by the enzyme CYP2C19 in the liver, but has few overall drug interactions. Coadministration with other antiepileptic drugs (such as carbamazepine, phenytoin, etc.) may slightly affect their metabolic rate, but generally no major dose adjustment is required. Avoid using it in combination with alcohol or central nervous system depressant drugs to avoid increasing side effects such as drowsiness and movement coordination disorders.

Reference materials:https://www.briviact.com/